Fund Holdings — Sands Capital Alternatives, LLC

Total Portfolio Value:
$414.66M
Total Bought:
$76.51M
Total Sold:
$69.84M
Net Transaction:
+$6.67M
Notable People:
Sands Capital Management, Lp, Erin Elizabeth Soule
Securities
▲▼
SharesValue
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Nu Holdings Ltd.CL A(NU)9,155,6619,155,6610$76.27M$109.23M26.34%+$32.96M
Klaviyo, Inc.COM SER A(KVYO)471,2603,514,897+3,043,637$13.09M$89.56M21.60%+$76.47M
DoorDash, Inc.CL A(DASH)603,288523,091-80,197$59.66M$72.04M17.37%+$12.38M
UiPath, Inc.CL A(PATH)2,303,4522,303,4520$57.22M$52.22M12.59%-$5.00M
Snowflake Inc.CL A(SNOW)215,843215,615-228$42.95M$34.84M8.40%-$8.11M
10x Genomics, Inc.CL A(TXG)481,770481,7700$26.96M$18.08M4.36%-$8.88M
Acumen Pharmaceuticals, Inc.(ABOS)3,417,0753,417,0750$13.12M$13.84M3.34%+$717.6K
Acrivon Therapeutics Inc1,652,6051,652,6050$8.13M$11.82M2.85%+$3.69M
Tarsus Pharmaceuticals, Inc.(TARS)260,000170,000-90,000$5.26M$6.18M1.49%+$914.5K
Taysha Gene Therapies, Inc.(TSHA)724,873724,8730$1.28M$2.08M0.50%+$797.4K
908 Devices Inc.(MASS)237,258237,2580$2.66M$1.79M0.43%-$870.7K
Candel Therapeutics, Inc.(CADL)811,737811,7370$1.19M$1.28M0.31%+$89.3K
Spruce Biosciences Inc787,007787,0070$2.31M$621.7K0.15%-$1.68M
Absci Corporation57,80457,8040$242.8K$328.3K0.08%+$85.5K
Coupang, Inc.CL A(CPNG)10,45111,931+1,480$169.2K$212.3K0.05%+$43.0K
Toast, Inc.CL A(TOST)7,8655,947-1,918$143.6K$148.2K0.04%+$4.6K
Samsara Inc.CL A(IOT)3,5703,5700$119.2K$134.9K0.03%+$15.7K
Datadog, Inc.CL A(DDOG)1,0151,0150$123.2K$125.5K0.03%+$2.3K
CrowdStrike Holdings, Inc.CL A(CRWD)344279-65$87.8K$89.4K0.02%+$1.6K
GitLab Inc.CL A(GTLB)6586580$41.4K$38.4K0.01%-$3.1K
Rayzebio, Inc.778,9220-778,922$48.43M$0—-$48.43M
Page 1 of 1
Sands Capital Alternatives, LLC — 13F Holdings — Q1 2024 | TickerTrail